Current reports

Warning: simplexml_load_file(): SSL: Connection reset by peer in /usr/home/sniznik/domains/celonpharma.com/public_html/wp-content/themes/celon/category-raporty-biezace.php on line 22 Warning: simplexml_load_file(https://www.gpw.pl/wyniki/a45_u__8c/n_CLN_full_data.html): failed to open stream: HTTP request failed! in /usr/home/sniznik/domains/celonpharma.com/public_html/wp-content/themes/celon/category-raporty-biezace.php on line 22 Warning: simplexml_load_file(): I/O warning : failed to load external entity "https://www.gpw.pl/wyniki/a45_u__8c/n_CLN_full_data.html" in /usr/home/sniznik/domains/celonpharma.com/public_html/wp-content/themes/celon/category-raporty-biezace.php on line 22

Current report No. 10/2022 – Submission of an application to the Food and Drug Administration (FDA) for the granting the Breakthrough Designation to Falkieri (Celon’s esketamine DPI) in treatment-resistant bipolar depression therapy

The Management Board of Celon Pharma S.A. (the “Company”) hereby informs that on April 20, 2022 an application was submitted to the Food and Drug Administration (FDA) for the granting of the Breakthrough Designation to Falkieri (Celon’s esketamine DPI) in treatment-resistant bipolar depression therapy. This application is supported by results of pre-clinical and clinical trials,Read more »

Current report No. 9/2022 – Submission of an application to the Food and Drug Administration (FDA) concerning the commencement of a clinical trial for Falkieri (Celon’s esketamine DPI)

The Management Board of Celon Pharma S.A. (the “Company”) hereby informs that on April 20, 2022 an application was submitted to the Food and Drug Administration (FDA) concerning the commencement of a clinical trial for Falkieri (Celon’s esketamine DPI) as a therapy for treatment-resistant bipolar depression under the so-called Investigational New Drug (IND) Application procedure.Read more »

Current report No. 8/2022 – Allocation of A series subscription warrants to eligible persons under the Incentive Program

Current report No. 8/2022Date prepared: 2022-04-15Abbreviated name of the issuer: CELON PHARMA S.A.Subject: Allocation of A series subscription warranties to eligible persons under the Incentive Program for persons of key importance to the CompanyLegal basis: Article 17 section 1 of the Market Abuse Regulation (MAR) – inside information.Content of the report:The Management Board of CelonRead more »

March 11, 2022 – Current report no. 6/2022 – Wydanie 30.000 akcji serii C w ramach warunkowego podwyższenia kapitału zakładowego

The Management Board of Celon Pharma S.A. (“Company”) informs that on March 11, 2022, 30,000 series C shares of the Company, with a nominal value of PLN 0.10 each, were entered in the securities accounts of the entitled persons, as part of the conditional increase of the Company’s share capital (“Shares”). The Shares were takenRead more »

February 21, 2022 – Current Report no. 5/2022 – Conclusion of a license purchase agreement

Legal basis: Article 17 section 1 of the Market Abuse Regulation (MAR) – inside information.Date: February 21, 2022, time: 22:18 p.m.The Management Board of Celon Pharma S.A. (“Company”) informs that on February 20, 2022, it learned about the conclusion of an agreement with the Salk Institute for Biological Studies (“Salk”) on the purchase of a

February 16, 2022 – Current Report No. 4/2022 – The KDPW statement on concluding an agreement on the registration of the Company’s series C shares

Legal basis: Article 56 section 1 point 2 Act on Public Offering – current and periodic information.Date: February 16, 2022.The abbreviated name of the issuer CELON PHARMA S.A.Subject: The KDPW statement on concluding an agreement on the registration of the Company’s series C shares The Management Board of Celon Pharma SA (the “Company”) hereby informsRead more »

January 21, 2022 – Current Report No. 3/2022 – Phase II clinical trial of CPL’280 in treatment of type 2 diabetes commenced

Legal basis: Article 17 section 1 of the Market Abuse Regulation (MAR) – inside information. Date: January 21, 2022, time: 05:08 p.m. The Management Board of Celon Pharma S.A. (“Company”) announces that on January 21, 2022, it learned about the inclusion of the first patient in the Phase II clinical trial of CPL’280, a second-generationRead more »

Current report No. 2/2022 – Obtaining information concerning a European patent for esketamine inhalation formulation and expanding patent protection beyond the treatment of treatment-resistant depression

In reference to current report No. 52/2021, the Management Board of Celon Pharma S.A. (“Company”) hereby informs that on January 10, 2022 it received specifications of European patents No. EP 3 731 815 B1 and EP 3 505 157 B1 for esketamine inhalation formulation, the granting of which was announced in “European Patent Bulletin 21/49” of December 8, 2021.

Current report No. 1/2022 – Dates for submitting periodical reports in 2022

Acting pursuant to Article 80 subs. 1 of the Regulation of the Minister of Finance of 29 March 2018 on current and periodic information provided by issuers of securities […], the Management Board of Celon Pharma S.A. announces the dates for submitting periodical reports in 2022